MedTrace Logo

Study to Evaluate the Effect of Megestrol Acetate in Severe Chronic Obstructive Pulmonary Disease With Loss of Weight

NCT00507949 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2011-06-08

No results posted yet for this study

Summary

The purpose of this trial is to study the effect of megestrol acetate in the gain of body weight in patients with severe Chronic obstructive pulmonary disease in order to improve the survival of the patients.

Conditions

Interventions

DRUG

Megestrol acetate

Sachets of 160 mg of granulated. Dosage 160 mg /b.i.d. Duration 8 weeks.

DRUG

placebo

sachets of granulate of 160 mg. Dosage 160 mg b.i.d. Duration 8 weeks.

Sponsors & Collaborators

  • Rottapharm Spain

    lead INDUSTRY

Principal Investigators

  • Herrejon Alberto, MD · Hospital Universitario Dr. Peset, Valencia

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-10-31
Primary Completion
2009-04-30
Completion
2009-09-30

Countries

  • Spain

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00507949 on ClinicalTrials.gov